ArticleWiener klinische Wochenschrift2026
Noninvasive test patterns across vascular and parenchymal liver diseases.
Article in Wiener klinische Wochenschrift, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
BACKGROUND AND
aimsVascular liver diseases such as porto-sinusoidal vascular disorder (PSVD), Budd-Chiari syndrome (BCS), and non-cirrhotic portal vein thrombosis (NCPVT) are rare causes of portal hypertension (PH) but share the same phenotype with parenchymal chronic liver disease (CLD). We assessed whether blood-based and elastography-based noninvasive tests (NITs) can: (i) differentiate vascular from parenchymal liver disease, (ii) detect specific signs of portal hypertension within etiologies and (iii) identify portal vein thrombosis.
methodsConsecutive patients with PSVD, NCPVT, BCS, or CLD treated at a tertiary referral center between January 2022 and December 2024 were included. Assessed NITs included platelet count, liver stiffness measurement (LSM), spleen stiffness measurement (SSM), the SSM to LSM ratio, ANTICIPATE, and NICER.
resultsThis study included 411 patients: PSVD n = 43, NCPVT n = 38, CLD n = 309, and BCS n = 21. Among patients without PVT, NIT patterns differed between etiologies. The PSVD showed low LSM despite elevated SSM, resulting in the highest SSM to LSM ratio. This ratio best discriminated PSVD from CLD and BCS (AUC ≥ 0.870); the proposed cut-off of > 2 showed good diagnostic performance. The ANTICIPATE also differentiated PSVD from CLD/BCS, whereas SSM alone did not. Detection of specific PH signs was etiology dependent. In PSVD, platelet count showed the highest accuracy (AUC 0.823). In CLD, several NITs were associated with specific PH signs but accuracy was limited. In BCS, differences of the tested NITs for specific PH signs were not statistically significant. Across etiologies, NITs showed limited accuracy for detecting PVT.
conclusionCombined assessment of LSM and SSM, particularly the SSM to LSM ratio, supports differentiation of PSVD from parenchymal and posthepatic liver disease, whereas platelet counts was most informative to detect specific PH signs within PSVD.
Indexed as
Identifiers
42693274What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.